Newly activated UI Cancer Center clinical trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on For more information or questions about a study, please email or call 312-355-5112.

BTCRC HEM15-028: Phase I/II Study of Ixazomib and Romidepsin in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL). Phase I portion to evaluate maximum tolerated dose of Ixazomib plus Romidepsin. Phase II portion to determine the complete response rate of this combination in relapsed/refractory PTCL.
Sponsor: Big Ten Cancer Research Consortium
Principle Investigator: David Peace, MD

A031102: A randomized Phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors. NCT02375204
Sponsor: Alliance for Clinical Trials in Oncology
Principle Investigator: Dominic Ho, MC

Translate »